General Information of the Drug (ID: M6APDG03201)
Name
F-12509A
Status
Terminated
Structure
Formula
C21H28O4
InChI
1S/C21H28O4/c1-12-6-7-17-20(2,3)8-5-9-21(17,4)14(12)10-13-18(24)15(22)11-16(23)19(13)25/h11,14,17,22,25H,1,5-10H2,2-4H3/t14-,17-,21+/m0/s1
InChIKey
KFAYECQGXSDHKU-XXHMAFKTSA-N
PubChem CID
9862964
TTD Drug ID
D0O0JH
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Sphingosine kinase 1 (SPHK1)
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
Response Summary Sphingosine kinase 1 (SPHK1) is a therapeutic target for F-12509A. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of F-12509A through regulating the expression of Sphingosine kinase 1 (SPHK1). [1], [2]
References
Ref 1 ALKBH5 Regulates SPHK1-Dependent Endothelial Cell Angiogenesis Following Ischemic Stress. Front Cardiovasc Med. 2022 Jan 20;8:817304. doi: 10.3389/fcvm.2021.817304. eCollection 2021.
Ref 2 Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma. Oncotarget. 2016 Dec 6;7(49):80586-80598. doi: 10.18632/oncotarget.13014.